nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—Respiratory distress—Fludarabine—lymphatic system cancer	0.0314	0.0314	CcSEcCtD
Methyclothiazide—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0247	0.0247	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.0215	0.0215	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.0203	0.0203	CcSEcCtD
Methyclothiazide—Respiratory distress—Vincristine—lymphatic system cancer	0.0192	0.0192	CcSEcCtD
Methyclothiazide—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0182	0.0182	CcSEcCtD
Methyclothiazide—Jaundice—Mechlorethamine—lymphatic system cancer	0.0168	0.0168	CcSEcCtD
Methyclothiazide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Methyclothiazide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Vincristine—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Vincristine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Methyclothiazide—Vertigo—Mechlorethamine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Methyclothiazide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.012	0.012	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Methyclothiazide—Pneumonia—Fludarabine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.011	0.011	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.011	0.011	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Methyclothiazide—Anorexia—Mechlorethamine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Methyclothiazide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00954	0.00954	CcSEcCtD
Methyclothiazide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00946	0.00946	CcSEcCtD
Methyclothiazide—Agitation—Teniposide—lymphatic system cancer	0.00911	0.00911	CcSEcCtD
Methyclothiazide—Leukopenia—Teniposide—lymphatic system cancer	0.00887	0.00887	CcSEcCtD
Methyclothiazide—Malnutrition—Fludarabine—lymphatic system cancer	0.00871	0.00871	CcSEcCtD
Methyclothiazide—Pneumonia—Bleomycin—lymphatic system cancer	0.00822	0.00822	CcSEcCtD
Methyclothiazide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00808	0.00808	CcSEcCtD
Methyclothiazide—Agitation—Fludarabine—lymphatic system cancer	0.008	0.008	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00792	0.00792	CcSEcCtD
Methyclothiazide—Leukopenia—Fludarabine—lymphatic system cancer	0.0078	0.0078	CcSEcCtD
Methyclothiazide—Anorexia—Teniposide—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Methyclothiazide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00751	0.00751	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00722	0.00722	CcSEcCtD
Methyclothiazide—Pneumonia—Carmustine—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00711	0.00711	CcSEcCtD
Methyclothiazide—Decreased appetite—Teniposide—lymphatic system cancer	0.00703	0.00703	CcSEcCtD
Methyclothiazide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00698	0.00698	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Methyclothiazide—Rash—Mechlorethamine—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Methyclothiazide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00691	0.00691	CcSEcCtD
Methyclothiazide—Pneumonia—Vincristine—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Methyclothiazide—Anorexia—Fludarabine—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Methyclothiazide—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Methyclothiazide—Nausea—Mechlorethamine—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Methyclothiazide—Jaundice—Mitoxantrone—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Methyclothiazide—Urticaria—Teniposide—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Methyclothiazide—Body temperature increased—Teniposide—lymphatic system cancer	0.00639	0.00639	CcSEcCtD
Methyclothiazide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Methyclothiazide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Methyclothiazide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Methyclothiazide—Constipation—Fludarabine—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Methyclothiazide—Vasculitis—Methotrexate—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00601	0.00601	CcSEcCtD
Methyclothiazide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Methyclothiazide—Asthenia—Teniposide—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Methyclothiazide—Leukopenia—Bleomycin—lymphatic system cancer	0.00572	0.00572	CcSEcCtD
Methyclothiazide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00562	0.00562	CcSEcCtD
Methyclothiazide—Malnutrition—Carmustine—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Methyclothiazide—Diarrhoea—Teniposide—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Methyclothiazide—Vision blurred—Carmustine—lymphatic system cancer	0.00525	0.00525	CcSEcCtD
Methyclothiazide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Methyclothiazide—Vomiting—Teniposide—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Methyclothiazide—Agitation—Carmustine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Methyclothiazide—Asthenia—Fludarabine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Methyclothiazide—Rash—Teniposide—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Methyclothiazide—Dermatitis—Teniposide—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Methyclothiazide—Headache—Teniposide—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Methyclothiazide—Leukopenia—Carmustine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Methyclothiazide—Anorexia—Bleomycin—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Methyclothiazide—Agitation—Vincristine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Methyclothiazide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Methyclothiazide—Photosensitivity—Methotrexate—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Methyclothiazide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Methyclothiazide—Nausea—Teniposide—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Methyclothiazide—Vertigo—Vincristine—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Methyclothiazide—Leukopenia—Vincristine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Methyclothiazide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Methyclothiazide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Methyclothiazide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Methyclothiazide—Vomiting—Fludarabine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Methyclothiazide—Rash—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Methyclothiazide—Dermatitis—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Methyclothiazide—Headache—Fludarabine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Methyclothiazide—Anorexia—Carmustine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Methyclothiazide—Nausea—Fludarabine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Methyclothiazide—Urticaria—Bleomycin—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Methyclothiazide—Anorexia—Vincristine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Methyclothiazide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Methyclothiazide—Paraesthesia—Carmustine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Methyclothiazide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Methyclothiazide—Decreased appetite—Carmustine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Methyclothiazide—Paraesthesia—Vincristine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Methyclothiazide—Constipation—Carmustine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Methyclothiazide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Methyclothiazide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Methyclothiazide—Decreased appetite—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Methyclothiazide—Asthenia—Bleomycin—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Methyclothiazide—Constipation—Vincristine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Methyclothiazide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Methyclothiazide—Pancreatitis—Methotrexate—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Methyclothiazide—Constipation—Mitoxantrone—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Methyclothiazide—Body temperature increased—Carmustine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Methyclothiazide—Body temperature increased—Vincristine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Methyclothiazide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Methyclothiazide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Methyclothiazide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Methyclothiazide—Pneumonia—Methotrexate—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Methyclothiazide—Vomiting—Bleomycin—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Methyclothiazide—Rash—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Methyclothiazide—Dermatitis—Bleomycin—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Methyclothiazide—Asthenia—Carmustine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Methyclothiazide—Hypersensitivity—Vincristine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Methyclothiazide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Methyclothiazide—Asthenia—Vincristine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Methyclothiazide—Diarrhoea—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Methyclothiazide—Nausea—Bleomycin—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Methyclothiazide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Methyclothiazide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Methyclothiazide—Dizziness—Carmustine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Methyclothiazide—Diarrhoea—Vincristine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Methyclothiazide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Methyclothiazide—Vomiting—Carmustine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Methyclothiazide—Dizziness—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Methyclothiazide—Rash—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Methyclothiazide—Dermatitis—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Methyclothiazide—Headache—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Methyclothiazide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Methyclothiazide—Vomiting—Vincristine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Methyclothiazide—Rash—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Methyclothiazide—Dermatitis—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Methyclothiazide—Headache—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Methyclothiazide—Nausea—Carmustine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Methyclothiazide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Methyclothiazide—Rash—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Methyclothiazide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Methyclothiazide—Headache—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Methyclothiazide—Malnutrition—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Methyclothiazide—Nausea—Vincristine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Methyclothiazide—Nausea—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Methyclothiazide—Vision blurred—Methotrexate—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Methyclothiazide—Vertigo—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Methyclothiazide—Leukopenia—Methotrexate—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Methyclothiazide—Anorexia—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Methyclothiazide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Methyclothiazide—Decreased appetite—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Methyclothiazide—Urticaria—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Methyclothiazide—Body temperature increased—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Methyclothiazide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Methyclothiazide—Asthenia—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Methyclothiazide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Methyclothiazide—Dizziness—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Methyclothiazide—Vomiting—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Methyclothiazide—Rash—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Methyclothiazide—Dermatitis—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Methyclothiazide—Headache—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Methyclothiazide—Nausea—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
